UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 20, 2009
ARIAD Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 0-21696 | 22-3106987 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
26 Landsdowne Street, Cambridge, Massachusetts | 02139 |
(Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, including area code: (617) 494-0400
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01 Other Events.
On April 20, 2009 ARIAD Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the results of preclinical studies in support of the ongoing clinical evaluation of its oral investigational mTOR inhibitor, deforolimus, in patients with non-small cell lung cancer and certain other solid tumors. These findings, which are being presented by scientists from ARIAD’s partner, Merck & Co., Inc., at the annual meeting of the American Association for Cancer Research (AACR), provide further evidence of mTOR as a validated cancer target with potential clinical applicability in several different tumor types.
A copy of the press release is being filed herewith as Exhibit 99.1 and this information contained therein is incorporated by reference into this Current Report on Form 8-K.
ITEM 9.01 Financial Statements and Exhibits
| 99.1 | | Press Release dated April 20, 2009. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | ARIAD Pharmaceuticals, Inc. |
| | | |
Date: | April 20, 2009 | | By: | /s/ Edward M. Fitzgerald |
| | | | Edward M. Fitzgerald |
| | | | Senior Vice President, Chief Financial Officer |
Exhibit Index
Exhibit Number | | Description |
| | |
| 99.1 | | Press Release dated April 20, 2009. |
